Sign Up Today and Learn More About Emulate Stock
Invest in or calculate the value of your shares in Emulate or other pre-IPO companies through EquityZen's platform.
Emulate Stock (EMUL)
Organs-on-Chips Company
Emulate, Inc. is a private company focused on commercializing Organs-on-Chips as an automated human bioemulation platform that aims to mimic true human physiology so that responses to medicines, chemicals and diseases can be accurately predicted. Through co-innovation with collaborators and internal programs, Emulate aims to advance product innovation, design and safety across a range of applications in drug development, personalized medicine, agriculture and chemical-based consumer products. Emulate was founded in 2013 and is based in Bostom, MA. Notable investors in Emulate include Founders Fund, Glass Wall Syndicate, and Starlight Ventures.
About Emulate Stock
Founded
2013
Headquarters
Boston, MA, US
Total Funding
198M
Industries
Science and Engineering, Health Care, Biotechnology
Emulate develops Organs-on-Chips technologies through an automated human bioemulation platform that aims to mimic true human physiology so that responses to medicines, chemicals, and diseases can be accurately predicted. Through co-innovation with collaborators and internal programs, Emulate aims to advance product innovation, design, and safety across a range of applications in drug development, personalized medicine, agriculture, and chemical-based consumer products.
Emulate was founded in 2013 and is based in Bostom, MA. Notable investors in Emulate include Founders Fund, Glass Wall Syndicate, and Starlight Ventures.
Emulate Press Mentions
Stay in the know about the latest news on Emulate
Title: Global Organ on a Chip Market Projected to Surge from US$ 129.96 Million in 2023 to US$ 1,665.91 Million by 2032
einpresswire • Nov 06, 2024
EMulate Therapeutics Plans 2.5M Share IPO
marketwatch • Jan 05, 2023
Emulate Shares Positive Data on Key Liver Chip Tox Study
ow • Dec 10, 2022
Emulate launches new AAV transduction application for Liver-Chip
bioworld • Sep 22, 2022
EMulate Therapeutics Announces the Incorporation of Two Wholly Owned Subsidiaries
biospace • Nov 17, 2021
Investors in Emulate
Discover investors in Emulate stock and explore their portfolio companies
Emulate Management
Leadership team at Emulate
Chief Executive Officer
Jim Corbett
Chief Financial Officer
Scott Kantor
Join now and verify your accreditation status to gain access to:
- Emulate current valuation
- Emulate stock price
- Available deals in Emulate and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
How to invest in Emulate stock?
Accredited investors can buy pre-IPO stock in companies like Emulate through EquityZen funds. These investments are made available by existing Emulate shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Emulate stock?
Shareholders can sell their Emulate stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
